Esketamine Optimized the Efficacy of Dexmedetomidine in Treating Sleep Disorders with Comorbid Depression.
Neuropsychiatric disease and treatment January 1, 2025 Yitong Ding, Zhengye Wang, Jing Huang et al. 3 citations
Adding esketamine to dexmedetomidine improves sleep and depression in people with both insomnia and depression. In a randomized trial with 84 patients, those receiving both drugs after three days showed longer total sleep time, more deep (N3) sleep, less light (N2) and REM sleep, and lower depression and sleep rating scores compared to those given dexmedetomidine alone. Sleep improvements were linked to better depression scores and higher brain-derived neurotrophic factor levels. Dry mouth was the most common side effect. The combination extended sleep, deepened sleep continuity, and reduced depression with few adverse events.